Skip to main content

Growth Disorders

2
Pipeline Programs
5
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
2
GenotonormPhase 31 trial
GenotropinPhase 31 trial
Active Trials
NCT01073605Completed208Est. May 2009
NCT00174408Completed110Est. Feb 2005
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
easypod™N/A2 trials
Saizen® E-DevicePHASE_31 trial
Active Trials
NCT01582334Completed68Est. Dec 2015
NCT00738205Completed834Est. Jun 2009
NCT00450190Completed20Est. Sep 2006
Ipsen
IpsenChina - Tianjin
2 programs
rh IGF-1PHASE_31 trial
rhIGF-1PHASE_31 trial
Active Trials
NCT00330668Terminated114Est. Mar 2010
NCT00125164Completed137Est. Jul 2008
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
ZomactonN/A1 trial
Active Trials
NCT03274973Terminated4Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.Saizen® E-Device
Ipsenrh IGF-1
IpsenrhIGF-1
PfizerGenotonorm
PfizerGenotropin
Ferring PharmaceuticalsZomacton
Merck & Co.easypod™
Merck & Co.easypod™

Clinical Trials (8)

Total enrollment: 1,495 patients across 8 trials

NCT00450190Merck & Co.Saizen® E-Device

Saizen® E-Device User Trial

Start: Feb 2006Est. completion: Sep 200620 patients
Phase 3Completed
NCT00330668Ipsenrh IGF-1

Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency

Start: Nov 2005Est. completion: Mar 2010114 patients
Phase 3Terminated
NCT00125164IpsenrhIGF-1

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

Start: Mar 2004Est. completion: Jul 2008137 patients
Phase 3Completed
NCT01073605PfizerGenotonorm

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

Start: Jul 1993Est. completion: May 2009208 patients
Phase 3Completed
NCT00174408PfizerGenotropin

Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

Start: Mar 1990Est. completion: Feb 2005110 patients
Phase 3Completed
NCT03274973Ferring PharmaceuticalsZomacton

Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome

Start: May 2018Est. completion: Oct 20184 patients
N/ATerminated
NCT01582334Merck & Co.easypod™

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina

Start: Mar 2013Est. completion: Dec 201568 patients
N/ACompleted
NCT00738205Merck & Co.easypod™

Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

Start: Jun 2007Est. completion: Jun 2009834 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.